New immunotherapies go beyond CTLA-4 and PD(L)1 and show promising results for treating various types of cancer, including colorectal cancer.
Summer season is coming, and with it, time by the pool; but also possibly some more cases of “Margarita burn” or phytophotodermatitis.
In a first, haemodiafiltration was shown to have a lower risk of death than haemodialysis. Results could change current dialysis practice.
The combination was associated with deep and durable responses in previously untreated high-risk CLL, SLL, and del(17p) and/or TP53 mutations.
High-risk participants with heavily pre-treated relapsed or refractory follicular lymphoma benefitted in clinical remission and survival outcomes.
In a heavily pretreated population of participants with KMT2A rearranged acute leukaemia, revumenib displayed encouraging anti-tumour activity.
Harmful environmental influences, such as air and noise pollution or light pollution at night, can also contribute to susceptibility to disease.
Sovleplenib was associated with early and durable platelet responses in participants with primary immune thrombocytopenia.
Renizgamglogene autogedtemcel (reni-cel) established a swift and durable normalisation in haemoglobin and improvements in haemolysis markers.
Asciminib was superior to all other tested first-line tyrosine kinase inhibitors (TKIs) in participants with chronic myeloid leukaemia (CML).
Epcoritamab delivered encouraging efficacy data and a favourable safety profile in participants with high-risk Richter’s transformation (RT).
Mitapivat improved Hb levels and fatigue in participants with non-transfusion-dependent alpha or beta thalassaemia (NTDT) in a phase 3 study.
Treatment with pelabresib plus ruxolitinib was associated with improvements in all 4 hallmarks of myelofibrosis, the phase 3 MANIFEST-2 trial showed.
JAK inhibitor-naïve participants with myelofibrosis benefitted from a regimen of navitoclax plus ruxolitinib compared with ruxolitinib and a placebo.
The intestinal microbiome is essential in many body processes. Could prebiotic food intake benefit intestinal flora in intestinal polyps or colorectal carcinoma?
Anitocabtagene autoleucel (anito-cel) yielded excellent efficacy results in heavily pre-treated participants with relapsed or refractory multiple myeloma.
Isatuximab with bortezomib, lenalidomide + dexamethasone yielded better outcomes than VRd alone for first-line treatment of transplant-ineligible cases.
Treatment led to high measurable residual disease-negativity rates in European LeukaemiaNet subgroups for newly-diagnosed acute myeloid leukaemia.
The combination delivered a high rate of durable complete metabolic responses regardless of cell of origin in aggressive B-cell lymphoma patients.
Acalabrutinib added to bendamustine and rituximab decreased disease progression or death risks compared with BR and a placebo for mantle cell lymphoma.